Better Health for All

Hologic's core technologies, including systems for cervical and breast cancer screening, and diagnostic tests for HIV, hepatitis, and HPV, impacted over 193 million lives worldwide in 2024.

These products are entirely focused on health benefits, with no evidence of negative health outcomes. The company launched the Global Access Initiative in 2018, offering an all-inclusive pricing structure with no upfront costs for molecular diagnostic tests in nearly 50 countries, primarily in Africa and Southeast Asia. Through Project Health Equality, a multi-year initiative with over $20 million invested, Hologic addresses barriers to care for Black and Hispanic women in the U.S., collaborating with organizations to provide screening and diagnostic services in underserved communities. This initiative also includes a focus on education, developing culturally competent care models and improving public health policy. The company's emphasis on diagnostics and screening for diseases like cancer, HIV, and HPV demonstrates a strong focus on preventative health measures.

Fair Money & Economic Opportunity

Hologic Inc. is a medical technology company focused on women's health through medical devices and diagnostics, and is not directly involved in financial services or economic empowerment initiatives.

Consequently, the company does not offer lending, deposit services, consumer credit products, or financial education programs. Its operations do not generate customer finance data, nor is it regulated as a lender. While Hologic supports STEM education for underserved students, these philanthropic efforts do not align with the specific criteria of providing accessible lending, fair interest rates, or transparent banking services as defined by the 'Fair Money & Economic Opportunity' value.

Fair Pay & Worker Respect

As of the end of fiscal 2023, the female-to-male compensation ratio was 0.98.

The company conducts regular pay equity audits using regression analysis to control for variables such as job position, tenure, experience, performance, and location. Hologic educates managers, updates pay transparency policies, and expands benefits to address any pay equity discrepancies, targeting a gender compensation ratio of 1.0.

Honest & Fair Business

Hologic, Inc. faced significant scrutiny from the FDA regarding its BioZorb implantable marker. FDA inspection findings cited design control failures, inadequate verification and validation of design inputs, and delayed corrective actions for adverse events such as infections

. The FDA also cited violations in regulatory reporting, specifically the untimely submission of Medical Device Reports (MDRs) . In response, Hologic announced the discontinuation of the BioZorb product line and committed to resolving the identified issues and engaging closely with the FDA .

Kind to Animals

Hologic Inc. is listed on the Cruelty Free Investing animal use list due to its employment of animal testing in product development

, indicating that no products are certified cruelty-free. The company is not explicitly committed to cruelty-free research practices , suggesting a policy that permits animal testing, particularly in early-stage research .

No War, No Weapons

Hologic has secured contracts with the U.S. Department of Defense and the Department of Veterans Affairs for medical services and equipment. These include a $387,965.99 contract for mammography imaging services to the VA in 2024

, a $178.5 million contract in 2021 for SARS-CoV-2 assays , and a $721.1 million contract in 2017 for radiology systems . The company explicitly states these contracts align with peaceful initiatives, do not involve weapon production, and reinforce a non-military focus. This indicates 0% revenue from arms or defense contracts and no development or sale of dual-use technologies with military applications. Furthermore, the company confirms zero exposure to controversial or banned weapons.

Planet-Friendly Business

Hologic achieved a water intensity of 33 m³ per $1M revenue in 2024.

Its global landfill diversion rate was 65% in 2024. The company sourced 13% of its electricity from renewable sources in 2024, and 13% of its manufacturing sites are in water-stressed regions. Hologic has committed to Science Based Targets (SBTi) with validation pending, aiming for a 50% reduction in Scope 1 and 2 absolute emissions and a 25% reduction in specific Scope 3 categories by 2030 from a 2020 baseline, and a net-zero target by 2050 with a 90% absolute emission reduction. 34% of its strategic and preferred direct and indirect suppliers have committed to Science Based Targets. The company's reporting is aligned with TCFD recommendations, and it conducts comprehensive climate scenario analysis for 1.5°C, 2°C, and 3°C+ pathways across key facilities.

Respect for Cultures & Communities

The provided information indicates that no articles or data specifically link Hologic Inc. to initiatives concerning indigenous rights, cultural heritage, or local traditions.

Consequently, there is no evidence to assess the company against any of the KPIs for the 'Respect for Cultures & Communities' value.

Zero Waste & Sustainable Products

Hologic aims to reduce non-hazardous/non-recyclable waste by 15% by 2025.

The company initiated Project Reclaim, which refurbishes and reuses critical components from field units. This diverted electronic waste and resulted in over $1.5 million in savings. Additionally, Hologic's Costa Rica site achieved zero waste pre-certification by implementing comprehensive waste audits and disposal strategies. This included recycling various materials and diverting approximately 1.2 tons of organic waste monthly for composting.